As we begin 2022, many companies are still being impacted by the effects of the pandemic. At the top of that list is Teladoc Health ( NYSE:TDOC ) , the telehealth company that saw its usage and stock price surge during the height of the pandemic as patients needing medical care turned to its platform to see doctors virtually. Considering this backdrop, investors could expect to see Teladoc's results tapering off, fitting the company neatly into the pandemic stock narrative. However, the actual results over the past few quarters tell a different story. So should investors buy, sell, or hold Teladoc in 2022? Let's take a look. Image source: Getty Images. Continued strong growth In the third quarter of 2021, Teladoc reported year-over-year revenue growth of 81%, continuing a streak of sequential revenue growth since the beginning of 2019. On its own, the 81% revenue growth is excellent, but it's even more impressive considering that Q3 of 2020 featured growth of … [Read more...] about Teladoc Stock: Buy, Sell or Hold In 2022?
Best penny stock buy
Stocks rarely go straight up. When they do, the uncommon occurrence is called a "parabolic move." In stock terminology, such as move is defined by a sudden and dramatic increase in buying volume, thereby causing the company's share price to rapidly rise in a manner that resembles a parabola. Oddly enough, this phenomenon has happened on a far more regular basis in 2021 than at any other time in the history of the U.S. stock market. The most recent examples are the explosive upward moves by shares of Donald Trump's social media-associated stocks, Digital World Acquisition ( NASDAQ:DWAC ) and Phunware ( NASDAQ:PHUN ) . Last week, Digital World Acquisition's shares rose by as much as 1,500%. Phunware's shares, for their part, posted a jaw-dropping intraday high of over 2,000% during a single trading session last week. This week, it might be biotech 's turn at the parabolic-move game. Shares of Aurinia Pharmaceuticals ( NASDAQ:AUPH ) and Ocugen ( NASDAQ:OCGN … [Read more...] about 2 Biotech Stocks That Could Go Parabolic This Week
Berkshire Hathaway ( NYSE:BRK.A ) ( NYSE:BRK.B ) CEO Warren Buffett is widely considered as one of the greatest investors of all time. One of Buffett's keys to success -- and a core lesson learned from his mentor Benjamin Graham -- has been to invest with a so-called "margin of safety." This concept centers on the idea of buying stocks trading a substantial discount relative to their intrinsic value. While the intrinsic value of a stock means different things to different investors, one of the common themes across the galaxy of definitions for this time-tested investing concept is to focus on companies with strong free cash flows, a solid balance sheet, and a growing dividend program. By taking this approach, investors can essentially ignore the inherent volatility in the market from year to year and simply let the company's strong fundamentals do the heavy lifting, so to speak. Which Berkshire Hathaway holdings -- a.k.a. Warren Buffett stocks -- are the best buys during … [Read more...] about 2 Best Warren Buffett Dividend Stocks to Buy Now
For more than a decade, growth stocks have been the talk of Wall Street. Historically low lending rates have rolled out the red carpet for fast-paced companies and allowed them to borrow cheaply in order to hire, acquire, and innovate. But what you might not realize is that value stocks have actually outperformed growth stocks over the very long run. Since value stocks are profitable and time-tested, they're the perfect place for patient investors to put their money to work. Below are five value stocks that could make you richer in 2022. Image source: Getty Images. General Motors The days of General Motors ( NYSE:GM ) being just another stagnant auto stock are gone. The electrification of automobiles has placed a multi-decade growth opportunity on the company's doorstep, and it'll undoubtedly run with it. In June, General Motors announced plans to up its investments in electric vehicles (EVs), autonomous vehicles, and batteries to $35 billion by 2025 . The … [Read more...] about 5 Value Stocks That Can Make You Richer in 2022
Since the stock market bottomed out in March 2020, investors have enjoyed historic gains. It took less than 17 months for the broad-based S&P 500 to double from its bear market low. Furthermore, the widely followed index came close to tripling its long-term average annual return in 2021. Despite this incredible outperformance, amazing deals remain. Patient investors who buy into innovative companies with clear-cut competitive advantages have a real chance to see their initial investment compound many times over. If you have cash ready to invest and are willing to let time be your ally, the following four stocks all have the tools to turn $100,000 into $1 million by 2030. Image source: Getty Images. Teladoc Health There's no sugarcoating it: telehealth giant Teladoc Health ( NYSE:TDOC ) was one of 2021's biggest disappointments. After skyrocketing during the initial stages of the coronavirus pandemic, concerns about larger-than-expected losses tied to its … [Read more...] about 4 Stocks That Can Turn $100,000 Into $1 Million by 2030
The idea of buying Teladoc Health ( NYSE:TDOC ) in 2022 may make some investors nervous because the telemedicine stock sank 54% last year. And performance this year isn't off to a brilliant start, either. The shares have lost about 14% since Dec. 31. Investors are worrying that patients may abandon telemedicine after the pandemic ends. And that would mean Teladoc's best days are behind it. If that's the case, how will the still-unprofitable company make it to profitability? These are risks. But I also see some clues indicating these risks may not take shape. In fact, there are three great reasons to buy shares of Teladoc right now. Image source: Getty Images. 1. It's more than just a COVID stock Some investors viewed Teladoc as a "coronavirus stock" because patients flocked to online medical appointments -- instead of in-person ones -- during the early days of the health crisis. And those investors were right. The pandemic gave Teladoc the opportunity to attract more … [Read more...] about 3 Reasons to Buy Teladoc in 2022
While you might not like what I'm about to say, it's the truth: A stock market crash or steep correction may be brewing . Since the beginning of 1950, the benchmark S&P 500 has undergone 38 double-digit percentage declines, equating to roughly one every 1.9 years. Even though Wall Street doesn't strictly adhere to averages, it's important to recognize that crashes and corrections are a normal part of the investing cycle. On the other hand, dips in the market are also an incredible opportunity to pick up high-quality stocks at a discount. While there are numerous investing strategies that can make you richer over time, dividend stocks have a proven track record of outperforming their non-dividend-paying peers. Since dividend stocks are almost always profitable and time-tested, they're the perfect way to put money to work in a volatile market. If a stock market crash does occur in 2022, the following four dividend stocks would make for perfect buys. Image source: … [Read more...] about 4 Perfect Dividend Stocks to Buy if There’s a Stock Market Crash
There's a common expression in the investing community, which goes as follows: "It's a market of stocks, not a stock market." This essentially means that even with the financial markets at or near all-time highs as they are now, not all stocks have fared well. Pharma stock Amgen ( NASDAQ:AMGN ) is a perfect example. At its current share price of $204, the stock is just a touch above its 52-week low and a whopping 26% below its 52-week high. Let's look at whether you should interpret this recent poor stock performance as a buying opportunity or a sign to steer clear of Amgen. Image source: Getty Images. A solid third-quarter performance Amgen reported $6.7 billion in revenue during the third quarter, which equates to a 4.4% growth rate against the year-ago period. What led to Amgen's respectable performance? Given Amgen's diversified portfolio of more than two dozen drugs, there were quite a few moving parts affecting growth in the quarter. Legacy medications such … [Read more...] about Should You Buy This Giant Biotech Stock?
Biotech stocks haven't been at their best of late. The SPDR S&P Biotech Exchange Traded Fund ( NYSEMKT:XBI ) has lost more than 30% of its value over the prior 12 months. The XBI is thus bumping up against its 52-week low as of this writing. Investors have been backing away from biotech stocks over the past year for many reasons, including inflationary pressures, the risk of rising interest rates, the threat of fundamental drug pricing reform in the U.S., and the appeal of other high-growth asset classes like cryptocurrency. All isn't lost, however. Biotech, as a whole, is still going through an unprecedented period of innovation. As a result, scores of untapped, high-value therapeutic markets are starting to open up, a fact that bodes well for the industry's long-term fortunes. Savvy investors, in turn, would be wise to take advantage of this broad selloff in biotech. Which biotech stocks are the most attractive buys amid this turmoil? Here are my top three biotech … [Read more...] about My 3 Top Biotech Stock Picks for 2022
Loading up on growth stocks while they're at bargain prices can lead to some great long-term returns for investors. And with many of these stocks falling in recent weeks, there are plenty of good deals available right now. Among the cheapest stocks to consider include Bristol Myers Squibb ( NYSE:BMY ) and Dell Technologies ( NYSE:DELL ) . Both are trading at low earnings multiples and still possess many growth opportunities, so now could be an optimal time to add these safe investments to your portfolio. Image source: Getty Images. 1. Bristol Myers Squibb Although Bristol Myers pays an incredibly attractive 3.6% dividend yield, which is well above the S&P 500 average of 1.3%, you shouldn't overlook the growth potential here. Acquisitions have helped the company expand its top line (sales of $42.5 billion in 2020 were more than double the $20.8 billion Bristol Myers reported just three years earlier) and its portfolio of drugs. In 2019, Bristol Myers … [Read more...] about 2 Absurdly Cheap Growth Stocks to Buy in December